Thiogenesis Therapeutics, Corp.

Overview

Compare with another stock.

• TickerTTIPF on OTC²
• HeadquartersToronto, Canada²
• Incorporated inOntario, Canada⁴
• Business address4 King Street West, Suite 401, Toronto, A6 M5H 1B6⁴
• Legal formCorporation²
• LEI9845006CBA639FFD6454²
• StatusActive²
• LEI statusIssued and current²
• Registered address4 King W St, 401, M5H 1B6 Toronto, Canada²
• Registered withMinistry of Government and Consumer Services, 756372280²

See how the biggest companies compare on our leaderboards

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorBrook G. Riggins named Nov 25, 2022 to Jun 9, 2026⁵
• Executive Officer, DirectorPatrice G. Rioux named Nov 25, 2022 to Jun 9, 2026⁵
• DirectorChristopher G. Starr named Nov 25, 2022 to Jun 9, 2026⁵
• DirectorKim G. Tsuchimoto named Nov 25, 2022 to Jun 9, 2026⁵
• DirectorW. Hogan G. Mullally named Nov 25, 2022 to Jun 9, 2026⁵

Former names

• Rozdil Capital CorpAug 11, 2021 to Aug 11, 2021⁴

Timeline

1. May 3, 2018Founded Thiogenesis Therapeutics, Corp. is founded²

Calendar

Drug trials and FDA: coming up

1. Dec 2026Phase 2 trial readout expected Phase 2 trial of TTI-0102 (cysteamine-pantetheine disulfide) in Nephropathic Cystinosis: primary completion expected Dec 2026 (ClinicalTrials.gov NCT07837726).⁶
2. Jun 2027Phase 2 trial readout expected Phase 2 trial of TTI-0102: cysteamine-pantetheine disulfide and D-Mannitol in Leigh Syndrome: primary completion expected Jun 2027 (ClinicalTrials.gov NCT06990984).⁷

Drug trials and FDA: recently

1. Jan 12, 2026Phase 2 trial completed Phase 2 trial of TTI-0102 in MELAS Syndrome: primary completion Jan 12, 2026, no results posted yet (ClinicalTrials.gov NCT06644534).⁸

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

4 filings to the SEC since October 2021: 4 private raises. The latest 4:

1. Jun 9, 2026D EDGAR
2. Aug 8, 2025D EDGAR
3. Dec 20, 2023D EDGAR
4. Nov 25, 2022D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jun 1, 2026Raised $28,964 in a private offering of equity⁵ Form D: named in the filing: Patrice G. Rioux, W. Hogan G. Mullally, Kim G. Tsuchimoto, Brook G. Riggins, Christopher G. Starr Form D
2. Jul 30, 2025Raised $125,450 in a private offering of equity⁹ Form D: named in the filing: Patrice G. Rioux, W. Hogan G. Mullally, Brook G. Riggins, Christopher G. Starr, Kim G. Tsuchimoto Form D
3. Dec 15, 2023Raised $252,281 in a private offering of equity¹⁰ Form D: 1 investor so far Form D
4. Nov 18, 2022Raised $218,303 in a private offering of equity¹¹ Form D: 3 investors so far Form D

SEC filer profile

How Thiogenesis Therapeutics, Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARThiogenesis Therapeutics, Corp.¹
• CIK0001877778
• Incorporated inOntario, Canada¹
• Fiscal year endsFebruary 28¹
• Business address4 King Street West, Suite 401, Toronto, A6 M5H 1B6¹
• Phone6478467766¹
• On EDGAR sinceAug 11, 2021¹
• Filings5 in all: D (5)¹